Fama is an AI-based solution that identifies and offers an opportunity to address problematic behavior among potential hires and current employees by analyzing publicly available online information. This type of content can ultimately lead to brand risk and toxic culture, and is often missed in the hiring and management process.

BioMap is an AI-driven research and development company focusing on precision medicine. The company is committed to bringing first-in-class medicine to unmet medical needs for patients by applying modern A.I./Data science to the entire life cycle of drug discovery, with a long-term vision and strong funding. To design advanced, complex, and next-generation antibodies, BioMap's AI antibody design platform combines high throughput biological technologies with machine learning processes. Unsupervised learning is used to train a deep sequence representation model on hundreds of millions of protein sequences from various evolutionary models. This is applied to downstream tasks such as antibody structure prediction and biological activity prediction.

Incorporated in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existing data, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as a professional services and as a SaaS software platform. Iktos offers Makya™, ligand and structure-based de novo drug design platform for multi-parametric optimisation (MPO) of lead compounds in line with Target Candidate Profile (TCP). Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis.

Doppel serves a critical business function for protecting clients' brand and their customers. Their platform has given corporate partners peace of mind by scanning millions of domains, social media accounts, mobile apps, and more for phishing, account takeovers, and other digital threats. Doppel's AI models allow them to classify threats accurately and in real-time -- leading to faster takedowns. Doppel was established in 2022.

Douugh is a purpose-led fintech and neobank. Taking an AI first approach to autonomously helping customers better manage their money and live financially healthier lives.

Elementary is a full-stack robotics startup that tackles Machine Learning for robotic hardware from the ground up with the goal to create assistive tools to improve the human output of repetitive tasks. Elementary provides easy-to-use software, deep learning AI, and camera systems are built to capture visual data, deliver fast and reliable real-time judgments, and provide lasting value to the business. Elementary builds a hardware and software platform for applying machine learning and computer vision for intelligent automation of quality and traceability workflows in manufacturing and logistics.

Gravyty enables fundraisers to scale personalized outreach, qualify prospects faster, steward and deepen existing prospects and donors all while increasing revenue without additional staff.

Apella is an AI startup that brings modern engineering to improve surgery. It collects data from operating rooms in hospitals via sensors and puts artificial intelligence to the task of analyzing that information and spits it out in a way that that the startup says can be interpreted by hospitals to improve operations, surgical quality, training, and even real-time decision-making. Apella was founded in 2019 and is headquartered in San Francisco, California.